EA201890329A1 - СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ - Google Patents

СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ

Info

Publication number
EA201890329A1
EA201890329A1 EA201890329A EA201890329A EA201890329A1 EA 201890329 A1 EA201890329 A1 EA 201890329A1 EA 201890329 A EA201890329 A EA 201890329A EA 201890329 A EA201890329 A EA 201890329A EA 201890329 A1 EA201890329 A1 EA 201890329A1
Authority
EA
Eurasian Patent Office
Prior art keywords
connections
rorγ
rorγ modulators
formula
present
Prior art date
Application number
EA201890329A
Other languages
English (en)
Other versions
EA035063B1 (ru
Inventor
Джоанна Баконий
Стивен Ричард Брунетте
Делфин Коллин
Роберт Оуэн Хьюз
Сян Ли
Шуан Лян
Роберт Сибли
Майкл Роберт Тёрнер
Лифэнь Ву
Цян Чжан
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201890329A1 publication Critical patent/EA201890329A1/ru
Publication of EA035063B1 publication Critical patent/EA035063B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Настоящее изобретение охватывает соединения формулы (I)где переменные, определенные здесь, пригодны для модуляции RORγ и лечения заболеваний, связанных с модуляцией RORγ. Настоящее изобретение также охватывает способы получения соединений формулы (I) и содержащие их фармацевтические препараты.
EA201890329A 2014-04-14 2015-04-10 Соединения в качестве модуляторов ror гамма EA035063B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14

Publications (2)

Publication Number Publication Date
EA201890329A1 true EA201890329A1 (ru) 2018-07-31
EA035063B1 EA035063B1 (ru) 2020-04-23

Family

ID=52998264

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890329A EA035063B1 (ru) 2014-04-14 2015-04-10 Соединения в качестве модуляторов ror гамма
EA201691978A EA031351B1 (ru) 2014-04-14 2015-04-10 СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201691978A EA031351B1 (ru) 2014-04-14 2015-04-10 СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ

Country Status (36)

Country Link
US (5) US9242989B2 (ru)
EP (2) EP3131902B1 (ru)
JP (2) JP6282759B2 (ru)
KR (2) KR102410076B1 (ru)
CN (3) CN106132965B (ru)
AP (1) AP2016009403A0 (ru)
AR (2) AR100058A1 (ru)
AU (2) AU2015247983B2 (ru)
BR (2) BR122020020657B1 (ru)
CA (1) CA2944787C (ru)
CL (1) CL2016002421A1 (ru)
CY (1) CY1122012T1 (ru)
DK (1) DK3131902T3 (ru)
EA (2) EA035063B1 (ru)
ES (1) ES2744299T3 (ru)
HK (2) HK1244801A1 (ru)
HR (1) HRP20191579T1 (ru)
HU (1) HUE045847T2 (ru)
IL (2) IL247419B (ru)
LT (1) LT3131902T (ru)
MA (1) MA46373A (ru)
ME (1) ME03513B (ru)
MX (1) MX370780B (ru)
MY (1) MY182834A (ru)
NZ (1) NZ723530A (ru)
PE (2) PE20161572A1 (ru)
PH (2) PH12016502019B1 (ru)
PL (1) PL3131902T3 (ru)
PT (1) PT3131902T (ru)
RS (1) RS59170B1 (ru)
SG (1) SG11201608537SA (ru)
SI (1) SI3131902T1 (ru)
TW (2) TWI652268B (ru)
UA (2) UA120094C2 (ru)
UY (1) UY36077A (ru)
WO (1) WO2015160654A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132965B (zh) * 2014-04-14 2020-02-07 勃林格殷格翰国际有限公司 作为RORγ调节剂的化合物
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
RS62016B1 (sr) 2015-05-15 2021-07-30 Aurigene Discovery Tech Ltd Supstituisana jedinjenja tetrahidrohinolina kao modulatori ror gama receptora
JP6778259B2 (ja) * 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体
TN2018000188A1 (en) 2015-12-15 2019-10-04 Astrazeneca Ab Isoindole compounds
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
RS64348B1 (sr) 2018-05-03 2023-08-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivati benzimidazola kao modulatori orfan gama receptora (rorγ) srodnih retinoida i njihova farmaceutska upotreba
JP2022504780A (ja) 2018-10-18 2022-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 光学活性１－シクロプロピルアルキル－１－アミンのスケーラブルな合成
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
BR112022008293A2 (pt) 2019-10-31 2022-07-26 Jiangsu Hengrui Medicine Co Sal de adição de ácido de regulador de ror?, composições farmacêuticas, uso dos mesmos e métodos para preparar forma cristalina e composição farmacêutica
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2023216910A1 (zh) * 2022-05-07 2023-11-16 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
MX2012004644A (es) 2009-10-21 2012-05-08 Boehringer Ingelheim Int Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1.
AU2012262014B2 (en) * 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators
CN103930425B (zh) * 2012-05-14 2016-04-27 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
CN106132965B (zh) * 2014-04-14 2020-02-07 勃林格殷格翰国际有限公司 作为RORγ调节剂的化合物
JP6778259B2 (ja) * 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma

Also Published As

Publication number Publication date
CN106132965A (zh) 2016-11-16
US20170008894A1 (en) 2017-01-12
MY182834A (en) 2021-02-05
CN107266450A (zh) 2017-10-20
UA121255C2 (uk) 2020-04-27
EA031351B1 (ru) 2018-12-28
ES2744299T3 (es) 2020-02-24
CL2016002421A1 (es) 2017-03-24
JP2018065874A (ja) 2018-04-26
US9598415B2 (en) 2017-03-21
KR20200040917A (ko) 2020-04-20
NZ723530A (en) 2023-05-26
TW201625622A (zh) 2016-07-16
KR102410076B1 (ko) 2022-06-22
BR122020020657B1 (pt) 2022-12-20
UY36077A (es) 2015-10-30
PE20211002A1 (es) 2021-06-01
MA46373A (fr) 2019-08-07
UA120094C2 (uk) 2019-10-10
EP3131902B1 (en) 2019-06-12
EA201691978A1 (ru) 2017-02-28
HUE045847T2 (hu) 2020-01-28
KR102410069B1 (ko) 2022-06-20
DK3131902T3 (da) 2019-09-02
AR100058A1 (es) 2016-09-07
CN107266454B (zh) 2019-08-09
EP3131902A1 (en) 2017-02-22
US20180022749A1 (en) 2018-01-25
AU2019203027A1 (en) 2019-05-23
MX2016013342A (es) 2017-01-26
CA2944787C (en) 2023-03-14
AR119454A2 (es) 2021-12-22
PH12016502019A1 (en) 2017-01-09
AP2016009403A0 (en) 2016-08-31
AU2015247983A1 (en) 2016-09-08
TWI655192B (zh) 2019-04-01
CN106132965B (zh) 2020-02-07
BR112016021962B1 (pt) 2022-12-13
PL3131902T3 (pl) 2019-11-29
SI3131902T1 (sl) 2019-10-30
US20160075706A1 (en) 2016-03-17
HK1244801A1 (zh) 2018-08-17
HK1244800A1 (zh) 2018-08-17
US20150291607A1 (en) 2015-10-15
WO2015160654A1 (en) 2015-10-22
JP2017511357A (ja) 2017-04-20
AU2019203027B2 (en) 2020-07-09
PE20161572A1 (es) 2017-02-01
US20190002465A1 (en) 2019-01-03
ME03513B (me) 2020-04-20
CY1122012T1 (el) 2020-10-14
PT3131902T (pt) 2019-09-17
SG11201608537SA (en) 2016-11-29
CA2944787A1 (en) 2015-10-22
JP6463855B2 (ja) 2019-02-06
BR112016021962A2 (pt) 2023-01-20
PH12020500252A1 (en) 2021-07-26
PH12016502019B1 (en) 2017-01-09
TW201841915A (zh) 2018-12-01
EP3418280B1 (en) 2023-07-12
US9242989B2 (en) 2016-01-26
AU2015247983B2 (en) 2019-05-16
CN107266450B (zh) 2020-07-24
MX370780B (es) 2020-01-03
JP6282759B2 (ja) 2018-02-21
LT3131902T (lt) 2019-09-25
KR20160142396A (ko) 2016-12-12
EP3418280A1 (en) 2018-12-26
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
HRP20191579T1 (hr) 2019-11-29
CN107266454A (zh) 2017-10-20
IL263878B (en) 2019-11-28
RS59170B1 (sr) 2019-10-31
EA035063B1 (ru) 2020-04-23
TWI652268B (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
EA201890329A1 (ru) СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
PH12018502329A1 (en) Modulators of the integrated stress pathway
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201492219A1 (ru) Соединения и композиции для модуляции egfr активности
EA201790413A1 (ru) Антитела против tigit
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201991599A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
EA201790922A1 (ru) Ингибиторы бромодомена
EA201691541A1 (ru) Новые анти-baff антитела
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM